Lindsay has previously written for several political blogs focusing primarily on digital and entertainment media. She has since covered a wide range of topics in the media, including political ...

Alnylam has said it will not proceed with a clinical trial of its RNAi drug vutrisiran in the rare eye disorder Stargardt disease – at least for now – tying its decision to President Joe Biden ...

Regeneron has signed a collaboration deal potentially worth $1 billion with RNAi experts Alnylam Pharmaceuticals, to develop and commercialise drugs targeting eye, central nervous system (CNS ...

Regeneron and Alnylam are to research treatments for the chronic liver disease non-alcoholic steatohepatitis (NASH), under a new agreement. Alnylam specialises in treatments based around RNA ...

Alnylam and Sanofi have revealed full phase 3 data on their RNA interference (RNAi) drug patisiran, soundly beating a rival candidate from Ionis, inotersen. Both drugs target hereditary ATTR ...

Alnylam has been a pioneer in hereditary ATTR amyloidosis, getting approval in 2018 for the first drug to treat the rare disease, and has now launched a digital companion to help patients track ...

A focus on validating its science looks set to finally pay off for Alnylam in the next few years. Recent years have seen a rapid proliferation in the number of biotech companies with potentially ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

With the first amyloid-targeting drug now approved for Alzheimer’s disease, Alnylam has presented preliminary clinical results with a new candidate that could potentially be dosed as ...

Alnylam Pharma has made a name for itself, developing gene-silencing therapies for rare disorders, but its latest discovery could take it into a much larger category – metabolic and ...

With Takeda’s £46 billion acquisition of Shire, it’s been a busy year for pharma M&A – and according to analysts Datamonitor, the specialist biotechs Nektar, BioMarin and Alnylam are the ...

A mother is called to her child’s school for an urgent meeting with his teachers in the Norwegian film “Armand,” a riff on a claustrophobic courtroom thriller set in a primary school ...